European Notebook: New Pricing Models; G7 On Clinical Data Transparency; Early Access For Opdivo
Executive Summary
Novartis’s Jimenez calls for new outcomes-based pricing in Europe, and U.K. PM Cameron wants the results of vaccine clinical trials to be open and transparent post-Ebola, while patients gain pre-approval access to Bristol’s new PD-1 inhibitor.